Biomedical subjects
L F Johnson
Publications and source records attributed to L F Johnson.
Get moving--and fast.
Explore the source record for details and available documents.
Building a safety program from scratch.
Explore the source record for details and available documents.
Meetings in minutes--tailgate it!
Explore the source record for details and available documents.
Securing confined spaces.
Explore the source record for details and available documents.
Learning the language of LOTO.
Explore the source record for details and available documents.
Progress and problems in achieving the United States national target for completion of antituberculosis treatment.
SETTING: The target for antituberculosis treatment in the United States is for 90% of patients to complete therapy within 12 months. OBJECTIVE: To assess progress in achieving the US national target for tuberculosis treatment. DESIGN: A comparison of treatment outcome in two cohorts of patients with drug-susceptible tuberculosis in California-those reported in 1993-1994 (8488 patients) and 1995-1996 (7823 patients). Risk factors for delay in treatment completion (more than 12 months) were assessed. RESULTS: The percentage of cases completing treatment within 12 months increased in the 1995-1996 cohort (to 68.2%), primarily due to concomitant reductions in delays in treatment completion (to 11.1%) and defaulting (to 2.4%). Disparities in timely treatment completion narrowed over time and in nearly all subpopulations, especially in groups with lowest treatment completion in the 1993-1994 cohort. Remaining risk factors for delay in treatment completion included AIDS and older ages. A substantial percentage of patients died or moved before treatment completion. CONCLUSIONS: Despite recent improvements, completion of antituberculosis treatment in California has not reached the national target. Reaching this target will require further reductions in delays in treatment completion and deaths during treatment, and ensuring that patients who move eventually complete treatment.
Training to second nature.
Explore the source record for details and available documents.
Software utilization. Getting your money's worth.
Explore the source record for details and available documents.
Machine guarding. Avoiding Russian roulette.
Explore the source record for details and available documents.
Constructing peace of mind.
Explore the source record for details and available documents.
Fall protection. No time to train?
Explore the source record for details and available documents.
Complex transcriptional initiation pattern of the thymidylate synthase promoter in mouse tissues.
Thymidylate synthase (TS) is an essential enzyme that must be expressed in all proliferating cells. The mouse TS promoter lacks a TATA box and an initiator element and initiates transcription over a broad region in cultured fibroblasts. The goal of this study was to determine if expression of the TS gene in a variety of cells and tissues involves the use of alternative promoters or different patterns of transcriptional initiation sites. The amount of TS mRNA and the pattern of initiation sites were determined using S1 nuclease protection assays. We found that even though the amount of TS mRNA varied over a wide range, reflecting differences in cell proliferation rates, the pattern of initiation sites was nearly identical in all of the cell lines and tissues that were examined. Therefore transcription of the TS gene is directed by a single promoter that is capable of being expressed in a wide variety of cellular environments.